Background: ABT-494 is a selective Janus Kinase 1 inhibitor currently being evaluated in Phase 3 trials for treatment of rheumatoid arthritis (RA) at doses of 15 mg and 30 mg once daily using the extended-release tablet formulation. Exposure-response analysis of ECG data collected at early stage clinical trials has been recently adopted in regulatory guidelines as a tool to assess the proarrhythmic risk of investigational new drugs. Objectives: The objective of this work was to evaluate ABT-494 QT prolongation potential using exposure-response analysis of data collected in early Phase 1 studies. Methods: Doses of ABT-494 or placebo were administered to healthy subjects in two Phase 1 studies. Evaluated ABT-494 immediate-release regimens ranged from 1 mg to 48 mg single doses under fasting conditions and 3 mg to 24 mg twice daily under non-fasting conditions. Serial triplicate electrocardiograms and pharmacokinetic assessments were conducted. The relationship between change from baseline in Fridericia-corrected QT interval (QTcF) and ABT-494 plasma concentrations was characterized using linear mixed-effects modeling. To evaluate the ECG assay sensitivity, the change in QTcF from baseline to 2 hours post-dose was compared for subjects who received placebo under fasting and non-fasting conditions. Results: There was no statistically significant relationship between the change from baseline in the QTcF interval and ABT-494 plasma concentrations. The point estimate of the effect on QTcF for the highest concentration observed in the evaluated studies, which is approximately 4-fold higher than the mean C max of the highest RA Phase 3 dose, is -1.77 msec (with upper bound of the 95% one-sided confidence interval of 3.33 msec; lower than the regulatory threshold of concern of 10 msec). Food shortened the QTcF interval by 5.9 msec (2-sided 90% confidence interval of -9.6 to -2.1 msec), indicating that the ECG assay used in the studies had adequate sensitivity to detect the small change in QTcF caused by food. Conclusions: ABT-494 showed no potential for QT prolongation at the expected therapeutic and supra-therapeutic plasma exposures for the doses being used in Phase 3 RA trials. Background: Lesion of the cardiovascular system is associated with uncontrolled inflammation and immune defects in patients with Rheumatoid Arthritis (RA). There is an evidence of the close pathogenetic connection between rheumatoid inflammation and accelerated development of atherosclerosis. The first sing of atherosclerosis is endothelial dysfunction (ED). Objectives: Evaluate the effectiveness of NO donators (4,2% solution of arginine hydrochloride and L-arginine aspartate) in the correction of lipid and ED in patients with RA and secondary Raynaud's syndrome (RS). Methods: 68 patients with RA were examined. All patients were divided into 2 groups: (37 people with RA in combination with secondary RS) received basic therapy of RA (methotrexate 10-15 mg/wk.), antiplatelet and vasodilatory drugs; II group (31 people -RA in combination with secondary RS) got similar therapy plus NO donators (4,2% solution of arginine hydrochloride and L-arginine aspartate). The examination was carried out at the patient's admission to the hospital and the hospital and 3 months after the beginning of treatment. Endothelial function was assessed by determining the flow-mediated vasodilation of brachial artery (FMD), levels of endothelin-1, rheumatoid factor (RF), C-reactive protein (CRP), lipid profile (total cholesterol -TC, low density lipoprotein -LDL, highdensitylipoprotein -HDL and triglycerides -TG), index of intima/media (IM) and atherogenic index (AI). Results: Levels of TC, LDL, AI and MI indexes were significantly higher than the norm in 2 compared groups before the treatment and 3 months after its start (p<0,05). There were significant decreases in levels of lipid profile, IA and MI index in II group 3 months after treatment in comparison to benchmarks (TC by 13,3%, LDL by 16,1%, TG by 14,7%, AI index by 13,8% MI index by 12,7%,p<0,05) and they were significantly unchanged in I group (p<0,05). It was elucidated a direct reliable strong correlation in patients of II group between the level of FMD and endothelin-1 before treatment (r=0,73, p<0,05) and after treatment (r=0,69, p<0,05) . Symptoms of ED, levels of endothelin-1, RF, CRP were decreased in patients of both groups after the conducted therapy. It was established a proportionately reliable correction between CRP and LDL levels after treatment in II group of patient (r=0,63, p<0,05). Conclusions: 1.There is a lack of flow-mediated vasodilation of brachial artery in patients with RA and secondary RS, which can indicate a dysregulation of endothelial function. 2. The level of CRP is increased in patients with RA and secondary RS and is associated with the risk of hyperlipemia and atherosclerosis. 3. The usage of NO donators (4,2% solution of arginine hydrochloride and L-arginine aspartate) in the treatment of RA with secondary RS significantly reduces the levels of IA and IM index, the level of atherogenic lipoprotein fractions (TC, LDL and TG) and decreases the severity of ED, which leads to minimizing the risk of atherogenesis and its complications. 
